Spinogenix Announces FRAXA Research Foundation Support for PIs Leading Phase 2b Trial of Investigational Therapy SPG601 for People with Fragile X Syndrome (FXS)

Phase 2SPG601Positive

AI Analysis

Summary

Spinogenix announced FRAXA Research Foundation support for principal investigators leading a Phase 2b trial of SPG601, a first-in-class BK-modulator being developed for Fragile X Syndrome to address cognitive, emotional, and sensory symptoms.

Clinical Trial Data

Phase

Outcome Details

Phase 2b trial ongoing with FRAXA Research Foundation support for principal investigators

Importance:5/10

Sentiment:

0.30

Fragile X Syndromefirst-in-classBK-modulatorcognitive symptomsclinical-stage

Related Companies

$FCHS

Read the original article

Published by PR Newswire Biotech on March 2, 2026 1:30 PM

Read Original